Condition: Metastatic/Locally Advanced Non-Small-Cell Lung Cancer · Metastatic/Locally Pancreatic Ductal Adenocarcinoma · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
UNLOCK ASP3082 is an open label, single arm, multicenter, phase 2 platform study that aims to evaluate the mechanisms of action and resistance to ASP3082 in metastatic/locally advanced Non-Samll-Cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC) with the presence of KRAS G12D mutation. The two cohorts of patients are the following : i. cohort NSCLC : patients with NSCLC with KRAS G12D mutation. ii. cohort PDAC : patients with PDAC with KRAS G12D mutation. Patients enrolled in the both cohorts will receive treatment with ASP3082 at the dose of 600 mg QW thereafter in a 21-day cycle. ASP3082 will be administred in intravenous route until disease progression, unacceptable toxicity, or consent withdrawal. Tumor and blood samples will be collected at baseline, on-treatment and at the end of treatment visit only from patients who develop acquired resistance (acquired resistance is defined as a best response of CR, PR, or SD lasting more than 6 months, followed by PD).
This description comes directly from the study's public registry record.
Yohann Loriot, MD, PhD · +33 (0)1 42 11 42 11 · Yohann.LORIOT@gustaveroussy.fr
Chloé Serhal, PhD · +33 (0)1 42 11 42 11 ext 23 43 · chloe.serhal@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| Gustave Roussy | Villejuif, France, France | Recruiting |
| Institut Bergonié | Bordeaux, France | Not Yet Recruiting |
| Centre Georges François Leclerc | Dijon, France | Not Yet Recruiting |
| Institut Paoli Calmettes | Marseille, France | Not Yet Recruiting |
| Institut de Cancérologie de l'Ouest | Saint-Herblain, France | Not Yet Recruiting |
| Institut de Cancérologie de Lorraine | Vandœuvre-lès-Nancy, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07483983